We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
J&J's Arthritis Candidate Sirukumab Denied FDA Approval
Read MoreHide Full Article
Johnson & Johnson (JNJ - Free Report) announced that the FDA has denied approval to its investigational rheumatoid arthritis (RA) treatment, sirukumab, an IL-6 inhibitor, for want of additional safety data.
The FDA issued a complete response letter (CRL) for J&J’s Biologics License Application (BLA) for sirukumab which was filed in September last year.
The company is looking to get sirukumab approved for the treatment of adult patients with moderately to severely active RA who have had an inadequate response or are intolerant to one or more disease modifying anti-rheumatic drugs (DMARDs).
Regulatory applications are under review in EU and Japan as well. The proposed trade name for sirukumab is Plivensia.
So far this year, J&J’s share price has increased 13.8%, comparing unfavorably with a gain of 17% recorded by the industry it belongs to.
The CRL was somewhat expected as last month, FDA’s Arthritis Advisory Committee had not recommended approval of sirukumab, raising some safety concerns. The panel was concerned with the increased mortality rates for both the evaluated doses of (50 mg and 100 mg) of sirukumab.
The FDA in its CRL has asked for additional clinical data to further evaluate the safety of the candidate. J&J plans to meet with the FDA for a follow-up discussion. The CRL is expected to delay the drug’s approval, which was previously expected to happen this year.
In July this year, J&J’s partner for sirukumab, U.K. based drug giant GlaxoSmithKline plc (GSK - Free Report) , informed the termination of its collaboration with J&J.
We remind investors that Eli Lilly & Company (LLY - Free Report) and partner Incyte Corporation (INCY - Free Report) had also received a CRL for their experimental JAK inhibitor, baricitinib to treat RA as the FDA demanded additional data.
However, in August, the companies informed that they will re-submit the NDA for baricitinib much faster than previously expected as they will not be required to conduct an additional study. The NDA is expected to be re-submitted in January next year.
RA is a common, chronic, life-long, autoimmune disease that affects about 1.3 million people in the United States.
Earlier this month, credit bureau Equifax announced a massive data breach affecting 2 out of every 3 Americans. The cybersecurity industry is expanding quickly in response to this and similar events. But some stocks are better investments than others.
Zacks has just released Cybersecurity! An Investor’s Guide to help Zacks.com readers make the most of the $170 billion per year investment opportunity created by hackers and other threats. It reveals 4 stocks worth looking into right away.
Image: Bigstock
J&J's Arthritis Candidate Sirukumab Denied FDA Approval
Johnson & Johnson (JNJ - Free Report) announced that the FDA has denied approval to its investigational rheumatoid arthritis (RA) treatment, sirukumab, an IL-6 inhibitor, for want of additional safety data.
The FDA issued a complete response letter (CRL) for J&J’s Biologics License Application (BLA) for sirukumab which was filed in September last year.
The company is looking to get sirukumab approved for the treatment of adult patients with moderately to severely active RA who have had an inadequate response or are intolerant to one or more disease modifying anti-rheumatic drugs (DMARDs).
Regulatory applications are under review in EU and Japan as well. The proposed trade name for sirukumab is Plivensia.
So far this year, J&J’s share price has increased 13.8%, comparing unfavorably with a gain of 17% recorded by the industry it belongs to.
The CRL was somewhat expected as last month, FDA’s Arthritis Advisory Committee had not recommended approval of sirukumab, raising some safety concerns. The panel was concerned with the increased mortality rates for both the evaluated doses of (50 mg and 100 mg) of sirukumab.
The FDA in its CRL has asked for additional clinical data to further evaluate the safety of the candidate. J&J plans to meet with the FDA for a follow-up discussion. The CRL is expected to delay the drug’s approval, which was previously expected to happen this year.
In July this year, J&J’s partner for sirukumab, U.K. based drug giant GlaxoSmithKline plc (GSK - Free Report) , informed the termination of its collaboration with J&J.
We remind investors that Eli Lilly & Company (LLY - Free Report) and partner Incyte Corporation (INCY - Free Report) had also received a CRL for their experimental JAK inhibitor, baricitinib to treat RA as the FDA demanded additional data.
However, in August, the companies informed that they will re-submit the NDA for baricitinib much faster than previously expected as they will not be required to conduct an additional study. The NDA is expected to be re-submitted in January next year.
RA is a common, chronic, life-long, autoimmune disease that affects about 1.3 million people in the United States.
J&J carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Can Hackers Put Money INTO Your Portfolio?
Earlier this month, credit bureau Equifax announced a massive data breach affecting 2 out of every 3 Americans. The cybersecurity industry is expanding quickly in response to this and similar events. But some stocks are better investments than others.
Zacks has just released Cybersecurity! An Investor’s Guide to help Zacks.com readers make the most of the $170 billion per year investment opportunity created by hackers and other threats. It reveals 4 stocks worth looking into right away.
Download the new report now>>